BioCentury | Mar 14, 2019
Company News

Orphan Drug designation for Espero's long-acting anticoagulant

...Espero said FDA granted Orphan Drug designation to tecarfarin to prevent systemic thromboembolism of cardiac origin...
...atrial fibrillation. The company said there are no approves therapies for ESRD patients with AF. Tecarfarin...
...Espero Biopharma Inc. (Jacksonville, Fla.) said the compound is Phase III-ready. Elizabeth S. Eaton, Staff Writer tecarfarin (ati-5923) Espero...
BioCentury | Oct 19, 2015
Company News

Armetheon, Lee’s Pharmaceutical Holdings Ltd. deal

...Armetheon granted Lee’s Pharmaceutical exclusive rights to develop and commercialize tecarfarin in Taiwan, Thailand and China...
...plus royalties. Armetheon has an SPA from FDA for an open-label Phase III trial of tecarfarin...
BioCentury | Feb 6, 2015
Financial News

Armetheon raises $24.3M in series B

...Hsu. The company plans to start an open-label Phase III trial next half of anticoagulant tecarfarin...
...valves for whom anti-thrombin or Factor Xa inhibitors are contraindicated or not recommended. Kengatharan said tecarfarin...
...warfarin, Armetheon expects tecarfarin will need less frequent monitoring and produce fewer drug-drug interactions because tecarfarin...
BioCentury | May 5, 2014
Clinical News

Tecarfarin: SPA received

...Armetheon received an SPA from FDA for an open-label Phase III trial to evaluate oral tecarfarin...
...to start the trial in 1Q15. Armetheon Inc. , Menlo Park, Calif. Product: Tecarfarin (formerly ATI-5923...
BioCentury | Jun 11, 2012
Emerging Company Profile

Armetheon: Stopping the bleeding

...Therapeutics Inc. President Peter Milner co-founded Armetheon Inc. to take a second shot at developing tecarfarin...
...patients with renal insufficiency, a group whose needs aren't met by available therapies. Tecarfarin (formerly ATI-5923...
...warfarin, Armetheon expects tecarfarin will need less frequent monitoring and produce fewer drug-drug interactions because tecarfarin...
BioCentury | Apr 23, 2012
Company News

AshHill Pharmaceutical Investments LLC finance news

...ATI-5923 ) from ARYx Therapeutics Inc. (Pink:ARYX, Fremont, Calif.). ARYx reported Phase II/III data of tecarfarin...
BioCentury | Feb 22, 2010
Company News

ARYx cardiovascular, neurology, gastrointestinal news

...ARYx said it will seek "near-term value" from its pipeline. The company's pipeline also includes tecarfarin...
BioCentury | Oct 5, 2009
Finance

3Q Approvals/3Q Setbacks

...a Phase II trial to treat rheumatoid arthritis (RA) ARYx Therapeutics Inc. (NASDAQ:ARYX) Tecarfarin (formerly ATI-5923...
BioCentury | Aug 3, 2009
Strategy

What might fit

...rifamycin derivative Carotid atherosclerosis Missed primary endpoint in Ph III ARYx Therapeutics Inc. (NASDAQ:ARYX) Tecarfarin (ATI-5923...
BioCentury | Aug 3, 2009
Strategy

Questions of the heart

...AF patients spent in fibrillation by 83% vs. baseline in a Phase IIb trial. Its tecarfarin...
Items per page:
1 - 10 of 31